Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2020. február 26., szerda 12:20 |
Press Release |
|
Budapest, 26 February, 2020 (OTS) - Kedrion issues this press release to set the record straight regarding certain inaccurate and, in some cases, defamatory statements made recently in the Hungarian media concerning human blood plasma. Without speculating as to the purpose of these media statements, Kedrion seeks to improve the accuracy of the public discourse surrounding this issue by calling attention to the facts set out below. |
1. There is a surplus of human blood plasma collected by the
National Blood Transfusion Service ("NBTS" - in Hungarian: Országos
Vérellátó Szolgálat) in Hungary even beyond therapeutic use in
hospitals. This surplus - which is defined in Hungarian legal
terminology as "industrial plasma" - can be the source of precious
pharmaceutical product.
2. Kedrion's Hungarian subsidiary, HUMAN BioPlazma Kft. is the
only manufacturer in Hungary which is capable of turning industrial
plasma into medications.
3. Since 2008, NBTS, a state budget entity, has sold its surplus
industrial plasma to HUMAN BioPlazma Kft. (and not to Kedrion) for
processing, otherwise pursuant to a previous agreement between NBTS
and TEVA Gyógyszergyár Zrt., which agreement was assigned to HUMAN
BioPlazma Kft. HUMAN BioPlazma Kft. kept paying a market price set
yearly by mutual agreement.
4. At the urging of Hungary's Government Control Office ("GCO" -
in Hungarian: Kormányzati Ellenőrzési Hivatal), NBTS interrupted
this forwarding of industrial plasma to HUMAN BioPlazma Kft. in
2017. Since then, the plasma has been processed into medication
outside Hungary.
5. Also, at the urging of the GCO, NBTS brought a compensation
lawsuit for HUF 11.5 billion against HUMAN BioPlazma Kft. (but not
Kedrion). The first instance court found against NBTS on every
single ground of the claim. NBTS' appeal is pending.
6. Neither Kedrion, nor HUMAN BioPlazma Kft. is in financial
distress, and we affirm that certainly neither of them is heading
towards bankruptcy or insolvency of any sort. Kedrion and the wholly
owned Hungarian subsidiary HUMAN BioPlazma Kft. are part of a solid
group and among its shareholders there is an Italian government
entity CDP Equity S.p.A.
7. It is simply untrue that Kedrion were in any quarrel with the
Food and Drug Administration (FDA) of the US (see the latest at:
https://www.kedrion.com/kedrion-announces-fda-approval-its-plasma-fractionation-facility-melville).
8. HUMAN BioPlazma Kft. and Kedrion always prioritized Hungarian
demand for the medication produced from NBTS's industrial plasma.
These medications were made available to Hungarian patients at fair
prices. Beyond the economic benefits to Hungary of Hungarian
industrial plasma being processed into medications at a facility
within Hungary until 2017, it resulted in medical scientific
benefits too. It is therefore untrue that either NBTS or Hungary
would have suffered any loss from this long-term deal.
9. HUMAN BioPlazma Kft. and Kedrion was always available and
ready to cooperate with the government of Hungary and its agencies.
10. HUMAN BioPlazma Kft. and Kedrion refrain and will remain away
from engaging in the press and media commotion and will always
remain faithful to its primary mission: to secure patients care.
Corporate information:
HUMAN BioPlazma Kft. is the Hungarian subsidiary of the Italy-based
Kedrion Biopharma, existing since 2007. The Kedrion Group's main
pharmaceutical company, Kedrion S.p.A. is active in 100+ countries
and employs more than 2,600 people at 4 production sites worldwide
(2 in Italy, 1 in US and 1 in Hungary) and is capable to process
over 2 million liters of plasma per year. Kedrion S.p.A. purchased
the business quota of TEVA Gyógyszergyár Zrt. held in HUMAN
BioPlazma (practically the biochemical branch of the TEVA Gödöllő
plant) at the end of 2007.
HUMAN BioPlazma Kft. employs over 330 workers today in its
production plant, logistic centre, and in its seven plasma centres
collecting human blood plasma around Hungary. Kedrion S.p.A.
invested more than HUF 12 billion in expansion and infrastructural
development in Hungary in the last decade and HUMAN BioPlazma Kft.
tripled the number of its employees.
The medicinal products of HUMAN BioPlazma Kft. and Kedrion
Biopharma are stable blood derivatives which provide treatment for a
number of different disorders such as haemophilia, angioedema,
autoimmune and chronic neurological diseases and in critical care.
The plasma-derived therapies manufactured by HUMAN BioPlazma Kft.
are life-saving medicaments in 40-50 thousand cases every year in
Hungary.
Further information: pressoffice_hu@kedrion.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|